Established by the US Congress and the National Institutes of Health (NIH), the Foundation for the NIH (FNIH) is a major driver in advancing complex health issues. Earlier in the year, the FNIH announced the launch of a new study to investigate potential new biomarkers in patients with osteoarthritis (OA) of the knee or those at risk for the disease.
DRX DrugCompare provides the most comprehensive dose-specific price comparisons used by health plans, pharmacy benefit managers, drug store chains, and other vendors of pharmaceuticals.
Wishing to expand the development of novel treatment compounds and diagnostics for autoimmune diseases, Pfizer and Nodality have launched a collaborative effort to allow Pfizer the use of single-cell network profiling (SCNP) technology toward the development of new pharmaceutical compounds for autoimmune diseases, with an initial focus on lupus.
By David Hawk Berlin, Germany—A multidisciplinary task force formed under the aegis of the European League Against Rheumatism (EULAR) has for the first time developed recommendations for the management of medium-to-high-dose systemic glucocorticoid therapy in rheumatic diseases.
Page 1 of 3
Results 1 - 10 of 29
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology